BSXBoston Scientific

Healthcare

$42.75-56% 1Y

$42.75

$41.5852 weeks$104.98

Is the price fair?

Excellent

Undemanding: modest expectations priced in, cheap against its own history, and cheap vs its sector.

3 good

What the price assumes~+5% a year

Priced for ~5% a year FCF growth. The price demands less than its three-year revenue growth of 16% a year, expectations look modest.

Vs its own P/E rangecheaper than 89% of its own historyderived

Cheap vs its own history: P/E 17.3 vs a 61.6 median over 35 quarters (−72% vs median).

Vs sector (EV/EBIT)19.1×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BSX's price assumes

Boston Scientific trades at 17.3× earnings against 26.2× for the median Medical Devices name, cheaper than its own group.

17.3

Trailing P/E · Medical Devices median 26.2 · cheaper than the typical name in its group

Price / sales: 3.21
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 5.4%
Free cash flow yield · Medical Devices median 4.5%
Growth the price implies: +4.7%
Growth the price implies · The price pays for +4.7% free cash flow growth a year for a decade; the business has delivered +34% a year over the last three.